This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Legal Team Sues Drug Maker Hoffmann-La Roche Limited Over Popular Acne Medicine

According to the Canadian Dermatology Association, acne affects nearly 20% or 5.6 million Canadians. More than 80% of acne sufferers are between the ages of 12 and 24.

The lawyers say the Twamley case is being put forward as the face of the Accutane lawsuit and a test case for more than a dozen similar cases they are preparing to file against the company. Legate says, "This case will cast a light on the problem and we expect many other victims to come forward."

The lawsuit claims that that Hoffmann-La Roche was negligent because it failed to warn the public that the drug could cause inflammatory bowel disease.

Williams adds, "Accutane affects each person differently, so the harm and damages they suffer varies widely. By choosing to bring a mass tort, we believe the victims are well served as their medical damages can be properly assessed on an individual basis."

Legate & Associates is a London, Ontario-based personal injury law firm that serves southwestern Ontario.

Harrison Pensa is a full-service, 55-lawyer firm servicing southwestern, Ont., with offices in London and Toronto.

Download videos for broadcast purposes:

Lawsuit Overview | MP4 | 332MB  

Jennifer's Story | MP4 | 415MB

Legal Perspective | MP4 | 466MB  


Video with caption: "Legate & Associates and Harrison Pensa launch mass tort over acne drug Accutane". Video available at:

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs